Simcyp Papers RSS Feed

Rostami-Hodjegan A, Nurminen S, Jackson PR & Tucker GT

Sun, 1 Dec 1996 00:00:00 GMT

Caffeine metabolic ratios as markers of enzyme activity: a theoretical assessment.
Pharmacogenetics
6(2), 121-49, April 1996.

Tucker GT, Rostami-Hodjegan A & Jackson PR

Tue, 1 Dec 1998 00:00:00 GMT

The determination of drug metabolising enzyme activity in vivo: pharmacokinetics and statistical issues.
Xenobiotica
28(12), 1255-1273, December 1998.

Rostami-Hodjegan A, Kromer HK & Tucker GT

Tue, 1 Jun 1999 00:00:00 GMT

In vivo indices of enzyme activity-the effect of renal impairment on the assessment of CYP2D6 activity.
Pharmacogenetics
9(3), 277-286, June 1999.

Rostami-Hodjegan A, Funck-Brentano C, Kromer HK & Tucker GT

Tue, 1 Jun 1999 00:00:00 GMT

In vivo indices of enzyme activity-the effect of renal impairment on the assessment of CYP2D6 activity.
British Journal of Clinical Pharmacology
47, 577-578, 1999.

Tooley A, Rostami-Hodjegan A, Lennard MS & Tucker GT

Wed, 1 Dec 1999 00:00:00 GMT

Acute inhibition of methadone metabolism by ritonavir: projection of interaindividual variability from in vitro data.
British Journal of Clinical Pharmacology
48, 883-884, 1999.

Wilson ZE, Tooley A, Rostami-Hodjegan A, Ellis SW & Tucker GT

Tue, 1 Apr 2003 00:00:00 GMT

Determining values for human microsomal protein per gram of liver.
British Journal of Clinical Pharmacology
55, 418-419, April 2003.

Proctor NJ, Rostami-Hodjegan A & Tucker GT

Tue, 1 Apr 2003 00:00:00 GMT

ISEF: An intersystem extrapolation factor for use with recombinant cytochrome P450 expressed systems.
British Journal of Clinical Pharmacology
55, 437, April 2003.

Proctor NJ, Rostami-Hodjegan A & Tucker GT

Tue, 1 Apr 2003 00:00:00 GMT

In vitro prediction of population in vivo drug clearance using updated scaling factors.
British Journal of Clinical Pharmacology
55, 445, April 2003.

Johnson TN, Sabzghabaee A, Rostami-Hodjegan A & Tucker GT

Tue, 1 Apr 2003 00:00:00 GMT

Prediction of age related changes in midazolam clearance in children using SIMCYP.
British Journal of Clinical Pharmacology
55, 432-433, April 2003.

Yang J, Kjellsson M, Rostami-Hodjegan A & Tucker GT

Wed, 1 Oct 2003 00:00:00 GMT

The effects of dose staggering on metabolic drug-drug interactions.
European Journal of Pharmaceutical Sciences
20(2), 223-232, October 2003.

Rowland-Yeo K, Rostami-Hodjegan A & Tucker GT

Mon, 1 Dec 2003 00:00:00 GMT

Abundance of cytochromes P450 in human liver: a meta-analysis.
British Pharmacological Society Winter Meeting
University of London, December 2003.

Wilson ZE, Tooley A, Rostami-Hodjegan A, Ellis SW & Tucker GT

Mon, 1 Dec 2003 00:00:00 GMT

Reference values for the amount of microsomal protein and number of hepatocytes per gram of human liver.
Drug Metabolism Reviews
35(S1), 100, April 2003.

Proctor NJ, Rostami-Hodjegan A & Tucker GT

Mon, 1 Dec 2003 00:00:00 GMT

Sources of variability associated with quantitative predictions of drug clearance from recombinant CYP enzymes.
Drug Metabolism Reviews
35(S1), 101, April 2003.

Proctor NJ, Tucker GT & Rostami-Hodjegan A

Sun, 1 Feb 2004 00:00:00 GMT

Prediction of clearance from recombinantly expressed CYPs: Intersystem extrapolation factor (ISEF).
Xenobiotica
34(2), 151-178, Feruary 2004.

Johnson TN, Tucker GT & Rostami-Hodjegan A

Sat, 1 May 2004 00:00:00 GMT

Prediction of drug clearance and its variability in neonates, infants and children using Simcyp.
Paediatric and Perinatal Drug Therapy
Abstract L23, 6(1), 51, May 2004.

Johnson TN, Tucker GT & Rostami-Hodjegan A

Sat, 1 May 2004 00:00:00 GMT

A comparison of methods to predict drug clearance in neonates, infants and children.
British Journal of Clinical Pharmacology
Abstract, 57(5), 677-678, May 2004.

Tucker GT

Thu, 1 Jul 2004 00:00:00 GMT

Pharmacogenetics - expectations and reality.
British Medical Journal
329(7456), 4-6, July 2004.

Yang J, Tucker GT & Rostami-Hodjegan A

Fri, 1 Oct 2004 00:00:00 GMT

Cytochrome P450 3A expression and activity in the human small intestine.
Clinical Pharmacology & Therapeutics
76(4), 391, October 2004.

Tucker GT

Fri, 1 Oct 2004 00:00:00 GMT

Predicting drug-drug interactions: In vitro veritas?
European Journal of Pharmaceutical Science
23(Suppl 1), 13, October 2004.

Rostami-Hodjegan A & Tucker GT

Wed, 1 Dec 2004 00:00:00 GMT

In Silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions.
Drug Disc Today: Technologies
1(4), 441-448, December 2004.

Rowland-Yeo K, Howgate EM, Tucker GT & Rostami-Hodjegan A

Wed, 1 Dec 2004 00:00:00 GMT

Predicting the clearance of CYP2C9 substrates.
Drug Metabolism & Disposition
32(12),1522 (author reply 1523), December 2004.

Rostami-Hodjegan A & Tucker GT

Wed, 1 Dec 2004 00:00:00 GMT

In Silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Disc Today: Technologies, Vol 1 (4), December 2004, P441-448.

Özdemir M, Aktan Y, Rostami-Hodjegan A, Crewe KH & Tucker GT

Wed, 1 Dec 2004 00:00:00 GMT

Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH.
Journal of Clinical Pharmacology
44(12), 1398-1404, December 2004.

Johnson TN, Tucker GT & Rostami-Hodjegan A

Wed, 1 Dec 2004 00:00:00 GMT

Prediction of drug clearance from in vitro data for 10 drugs in neonates, infants and children using Simcyp.
Drug Metabolism Reviews
Abstract 680, 36(Suppl 1), 340, December 2004.

Johnson TN

Wed, 1 Jun 2005 00:00:00 GMT

Modelling approaches to dose estimation in children.
British Journal of Clinical Pharmacology
59(6), 663-669, June 2005.

Yang J, Jamei M, Rowland Yeo K, Tucker GT & Rostami-Hodjegan A

Tue, 1 Nov 2005 00:00:00 GMT

Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol.
European Journal of Pharmaceutical Sciences
26(3-4), 334-340, November 2005.

Johnson TN, Tucker GT, Tanner MS & Rostami-Hodjegan A

Thu, 1 Dec 2005 00:00:00 GMT

Changes in liver volume from birth to adulthood: a meta analysis.
Liver Transplantation
12(11), 1481-1493, December 2005.

Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT & Rostami-Hodjegan A

Sat, 1 Apr 2006 00:00:00 GMT

A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation.
Current Drug Metabolism
7(3), 315-334, April 2006.

Howgate EM, Rowland-Yeo K, Proctor NJ, Tucker GT & Rostami-Hodjegan A

Thu, 1 Jun 2006 00:00:00 GMT

Prediction of in vivo drug clearance from in vitro data.
I: Impact of inter-individual variability.
Xenobiotica
36(6), 473-497, June 2006.

Inoue S, Howgate EM, Rowland-Yeo K, Shimada T, Yamazaki H, Tucker GT & Rostami-Hodjegan A

Thu, 1 Jun 2006 00:00:00 GMT

Prediction of in vivo drug clearance from in vitro data.
II: Potential inter-ethnic differences.
Xenobiotica
36(6), 499-513, June 2006.

Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT & Rostami-Hodjegan A

Sat, 1 Jul 2006 00:00:00 GMT

Prediction of metabolic drug clearance in humans: In vitro-in vivo extrapolation vs allometric scaling.
Xenobiotica
36(7), 567-580, July 2006.

Yang J, Jamei M, Heydari A, Rowland-Yeo K, de la Torre R, Farre M, Tucker GT & Rostami-Hodjegan A

Wed, 1 Nov 2006 00:00:00 GMT

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.
Journal of Psychopharmacology
20(6), 842-849, November 2006.

Van LM, Heydari A, Yang J, Hargreaves J, Rowland-Yeo K, Lennard MS, Tucker GT & Rostami-Hodjegan A

Wed, 1 Nov 2006 00:00:00 GMT

The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
Journal of Psychopharmacology
20(6), 834-841, November 2006.

Johnson TN, Rostami-Hodjegan A & Tucker GT

Thu, 30 Nov 2006 00:00:00 GMT

Prediction of clearance of eleven drugs and associated variability in neonates, infants and children.
Clinical Pharmacokinetics
45(9), 931-956, September 2006.

Christensen H, Baker M, Tucker GT & Rostami-Hodjegan A

Fri, 1 Dec 2006 00:00:00 GMT

Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data.
Journal of Pharmaceutical Sciences
95(12), 2778-2787, December 2006.

Barter ZE, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lipscomb JB, Pelkonen OR, Tucker GT & Rostami-Hodjegan A

Tue, 2 Jan 2007 00:00:00 GMT

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.
Current Drug Metabolism
8(1), 33-45, January 2007.

Dickinson GL, Rezaee S, Proctor NJ, Lennard MS, Tucker GT & Rostami-Hodjegan A

Tue, 2 Jan 2007 00:00:00 GMT

Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphisms on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application.
Journal of Clinical Pharmacology
47(2), 175-186, February 2007.

Dickinson GL, Lennard MS, Tucker GT & Rostami-Hodjegan A

Mon, 29 Jan 2007 00:00:00 GMT

The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies - CYP2C9 and warfarin as an example.
British Journal of Clinical Pharmacology
64(1), 14-26, July 2007.

Rostami-Hodjegan A & Tucker GT

Mon, 29 Jan 2007 00:00:00 GMT

Simulation and prediction of in vivo metabolic drug clearance from in vitro data.
Nature Reviews
6(2), 140-149, February 2007.

Van LM, Swales J, Hammond C, Wilson C, Hargreaves JA & Rostami-Hodjegan A

Mon, 19 Feb 2007 00:00:00 GMT

Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA).
European Journal of Pharmaceutical Sciences
31(1), 53-61, May 2007.

Yang J, Jamei M, Rowland-Yeo K, Rostami-Hodjegan A & Tucker GT

Tue, 6 Mar 2007 00:00:00 GMT

Misuse of the well-stirred model of hepatic drug clearance.
Drug Metabolism & Disposition
35(3), 501-502, March 2007.

Van LM, Hargreaves JA, Lennard MS, Tucker GT & Rostami-Hodjegan A.

Tue, 22 May 2007 00:00:00 GMT

Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.
European Journal of Pharmaceutical Sciences
32(1), 8-16, September 2007.

Yang J, Jamei M, Rowland Yeo K, Tucker GT & Rostami-Hodjegan A

Mon, 11 Jun 2007 00:00:00 GMT

Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition.
European Journal of Pharmaceutical Sciences
31(3-4), 232-241, July 2007.

Yang J, Jamei M, Rowland Yeo K, Tucker GT & Rostami-Hodjegan A

Tue, 2 Oct 2007 00:00:00 GMT

Prediction of intestinal first-pass drug metabolism.
Current Drug Metabolism
8(7), 676-684, October 2007.

Perrett HP, Barter ZE, Jones BC, Yamazaki H, Tucker GT & Rostami-Hodjegan A

Fri, 12 Oct 2007 00:00:00 GMT

Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes.
Drug Metabolism & Disposition
35(10), 1733-1736, October 2007.

Van LM, Sarda S, Hargreaves JA & Rostami-Hodjegan A

Mon, 14 Apr 2008 00:00:00 GMT

Metabolism of dextrorphan by CYP2D6 in different recombinantly expressed systems and its implications for the in vitro assessment of dextromethorphan metabolism.
European Journal of Pharmaceutical Sciences
In Publication, 2008.